This transaction
Establishment of subsidiaryThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Research and development, manufacturing and sales, and contract research, development and manufacturing of pharmaceutical and biotechnology-related products, primarily nucleic acid pharmaceuticals
The impact of this matter on the Company's consolidated results for the fiscal year ending March 2027 will be minor.
| Item | Details |
|---|---|
| Transaction name | Establishment of subsidiary |
| Name of the Subject Company | NuChord Co., Ltd. (ニュコード) |
| Business Description of the Subject Company | Research and development, manufacturing and sales, and contract research, development and manufacturing of pharmaceutical and biotechnology-related products, primarily nucleic acid pharmaceuticals |
| Location of the Subject Company | Minato-ku, Tokyo |
| Capital Stock of the Subject Company | ¥200 million |
| Date of Establishment of the Subject Company | 1 September 2026 |
| Voting rights ownership percentage | After 100% (before not disclosed) |
| Impact on Business Performance | The impact of this matter on the Company's consolidated results for the fiscal year ending March 2027 will be minor. |
| Execution Date / Effective Date | 1 September 2026 (established) |
| Management structure after acquisition | The company name is NuChord Co., Ltd. (ニュコード), and the representative director and president is Hoshikawa Hikaru (星川 光). Officers and employees of the Company will serve as officers and employees of the new company on secondment. The Company is also considering a future transition to a joint venture structure with YGK. |
Items this document does not state (22)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To commercialize the nucleic acid pharmaceutical CDMO business as a new growth engine and provide integrated services, from raw materials and intermediates through GMP manufacturing, by leveraging the technology and expertise of the Group. The Company is also considering a future transition to a joint venture structure with YGK.